Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2026)

Amylyx Pharmaceuticals has reported Current Leases for 5 years, with the latest figure at $1.0 million in Q2 2026.

• On a quarterly basis, Current Leases rose 51.58% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 51.58% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, down 17.06% from the prior year.
• Current Leases was $1.0 million for Q2 2026 at Amylyx Pharmaceuticals, down from $1.2 million in the prior quarter.
• The five-year high for Current Leases was $2.4 million in Q2 2024, with the low at $665000.0 in Q2 2025.
• Average Current Leases over 5 years is $1.7 million, with a median of $1.9 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Current Leases sank 71.93% in 2025, then jumped 51.58% in 2026.
• Over 5 years, Current Leases stood at $2.0 million in 2022, then gained by 10.64% to $2.3 million in 2023, then plunged by 32.74% to $1.5 million in 2024, then declined by 17.06% to $1.3 million in 2025, then retreated by 19.94% to $1.0 million in 2026.
• The last three Current Leases figures came in at $1.0 million (Q2 2026), $1.2 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.